Gowthami Mahendran

Ms. Gowthami Mahendran

Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA
orcid
Post-Doctoral Researcher at Hydrocephalus Research Center

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KSKrishna Shivakumar
Krishna Shivakumar
Gowthami MahendranGowthami Mahendran
Gowthami Mahendran
JBJessica Brown
Jessica Brown
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and multiple endocrine neoplasia-β (MENβ) are two long noncoding RNAs upregulated in multiple cancers, marking these RNAs as therapeutic targets. While traditional small-molecule and antisense-based approaches are effective, we report a locked nucleic acid (LNA)-based approach that targets the MALAT1 and MENβ triple helices, structures comprised of a U-rich internal stem-loop and an A-rich tract. Two LNA oligonucleotides resembling the A-rich tract (i.e., A9GCA4) were examined: an LNA (L15) and a phosphorothioate LNA (PS-L15). L15 binds tighter than PS-L15 to the MALAT1 and MENβ stem loops, although both L15 and PS-L15 enable RNA•LNA-RNA triple-helix formation. Based on UV thermal denaturation assays, both LNAs selectively stabilize the Hoogsteen interface by 5–13 °C more than the Watson–Crick interface. Furthermore, we show that L15 and PS-L15 displace the A-rich tract from the MALAT1 and MENβ stem loop and methyltransferase-like protein 16 (METTL16) from the METTL16-MALAT1 triple-helix complex. Human colorectal carcinoma (HCT116) cells transfected with LNAs have 2-fold less MALAT1 and MENβ. This LNA-based approach represents a potential therapeutic strategy for the dual targeting of MALAT1 and MENβ.

10 May 2022 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
Gowthami MahendranGowthami Mahendran
Gowthami Mahendran
OJOshadhi T. Jayasinghe
Oshadhi T. Jayasinghe
DTDhanushika Thavakumaran
Dhanushika Thavakumaran
GAGayan Mirihana Arachchilage
Gayan Mirihana Arachchilage
GSGayathri Silva
Gayathri Silva
Precise regulation of gene expression is crucial for living cells to adapt for survival in diverse environmental conditions. Among the common cellular regulatory mechanisms, RNA-based regulators play a key role in all domains of life. Discovery of regulatory RNAs have made a paradigm shift in molecular biology as many regulatory functions of RNA have been identified beyond its canonical roles as messenger, ribosomal and transfer RNA. In the complex regulatory RNA network, riboswitches, small RNAs, and RNA thermometers can be identified as some of the key players. Herein, we review the discovery, mechanism, and potential therapeutic use of these classes of regulatory RNAs mainly found in bacteria. Being highly adaptive organisms that inhabit a broad range of ecological niches, bacteria have adopted tight and rapid-responding gene regulation mechanisms. This review aims to highlight how bacteria utilize versatile RNA structures and sequences to build a sophisticated gene regulation network.

7 November 2024 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
Gowthami MahendranGowthami Mahendran
Gowthami Mahendran
KBKurtis Breger
Kurtis Breger
PMPhillip McCown
Phillip McCown
JHJacob P. Hulewicz
Jacob P. Hulewicz
TBTulsi Bhandari
Tulsi Bhandari
JBJessica Brown
Jessica Brown
Miller-Dieker syndrome (MDS) is a rare neurogenetic disorder resulting from a heterozygous deletion of 26 genes in the MDS locus on human chromosome 17. MDS patients often die in utero and only 10% of those who are born reach 10 years of age. Current treatments mostly prevent complications and control seizures. A detailed understanding of the pathogenesis of MDS through gene expression studies would be useful in developing precise medical approaches toward MDS. To better understand MDS at the molecular level, we performed RNA sequencing on RNA and mass spectrometry on total protein isolated from BJ (non-MDS) cells and GM06097 (MDS) cells, which were derived from a healthy individual and an MDS patient, respectively. Differentially expressed genes (DEGs) at the RNA and protein levels involved genes associated with phenotypic features reported in MDS patients (CACNG4, ADD2, SPTAN1, SHANK2), signaling pathways (GABBR2, CAMK2B, TRAM-1), and nervous system development (CAMK2B, BEX1, ARSA). Functional assays validated enhanced calcium signaling, downregulated protein translation, and cell migration defects in MDS. Interestingly, overexpression of methyltransferase-like protein 16 (METTL16), a protein encoded in the MDS locus, restored defects in protein translation, phosphor states of mTOR (mammalian target of rapamycin) pathway regulators, and cell migration in MDS cells. Although DNA- and RNA-modifying enzymes were among the DEGs and the intracellular SAM/SAH ratio was eightfold lower in MDS cells, global nucleoside modifications remained unchanged. Thus, this study identified specific genes and pathways responsible for the gene expression changes, which could lead to better therapeutics for MDS patients.

Verified
Journal Article
Open access
PDF file
Gowthami MahendranGowthami Mahendran
Gowthami Mahendran
JBJessica Brown
Jessica Brown
Miller–Dieker Syndrome (MDS) is a rare neurodevelopmental disorder caused by a heterozygous deletion of approximately 26 genes within the MDS locus of human chromosome 17. MDS, which affects 1 in 100,000 babies, can lead to a range of phenotypes, including lissencephaly, severe neurological defects, distinctive facial abnormalities, cognitive impairments, seizures, growth retardation, and congenital heart and liver abnormalities. One hallmark feature of MDS is an unusually smooth brain surface due to abnormal neuronal migration during early brain development. Several genes located within the MDS locus have been implicated in the pathogenesis of MDS, including PAFAH1B1, YWHAE, CRK, and METTL16. These genes play a role in the molecular and cellular pathways that are vital for neuronal migration, the proper development of the cerebral cortex, and protein translation in MDS. Improved model systems, such as MDS patient-derived organoids and multi-omics analyses indicate that WNT/β-catenin signaling, calcium signaling, S-adenosyl methionine (SAM) homeostasis, mammalian target of rapamycin (mTOR) signaling, Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling, and others are dysfunctional in MDS. This review of MDS integrates details at the clinical level alongside newly emerging details at the molecular and cellular levels, which may inform the development of novel therapeutic strategies for MDS.

21 February 2024
Verified
Book Chapter
Open access
PDF file
Gowthami MahendranGowthami Mahendran
Gowthami Mahendran
MSMargaret A. Schwarz
Margaret A. Schwarz
Functioning as a pivotal platform for energy production and transduction, mitochondria generate ATP to meet the dynamic demands of embryonic development. Consequently, disruption or alteration in mitochondrial activity influences not only cellular status, but also can impact organ formation. Disrupted mitochondrial performance not only impairs cardiovascular function but can also disrupt cardiac maturation through prevention of the myocardium’s transition between the trabeculation to the compaction phase. During embryonic development, proliferating cardiomyocytes create a trabecular mesh network. Gradual compaction of this network transforms the intra-trabecular spaces into the capillaries of the coronary circulation. Achievement of functional compaction and ultimately normal cardiac function is dependent in part on mitochondrial well-being with failure to complete remodeling of the inner trabecular layer contributing to disrupted endocardial vasculature and fibrosis, left ventricular noncompaction (LVNC). LVNC, commonly associated with mitochondrial genetic alterations, is speculated to occur due to an interruption during the process of compaction at the early developmental stages of the left ventricle (LV). Mitochondrial mutations, remain the common etiology of LVNC with a wide spectrum of these genes associated with other cardiomyopathies related to LVNC. Understanding the impact that mitochondrial genetic alterations have on the evolution of cardiac noncompaction could provide new treatment opportunities.

14 August 2026 in Sci
Verified
Journal Article
Open access
PDF file
Gowthami MahendranGowthami Mahendran
Gowthami Mahendran
PKPiriyankan Kirupaharan
Piriyankan Kirupaharan
Proteomics has emerged as a powerful tool for advancing our understanding of brain disorders by enabling large-scale characterization of protein expression, post-translational modifications, and interaction networks. Neurological conditions are often characterized by complex and dynamic molecular changes that are not fully captured by traditional diagnostic approaches. Proteomic technologies, particularly mass spectrometry-based and affinity-based methods, offer the ability to identify disease-specific protein signatures and elucidate underlying pathophysiological mechanisms, including neurodegeneration, neurodevelopment and neuroinflammation and alterations happening to the extracellular matrix and body fluid homeostasis. In recent years, artificial intelligence has emerged as a powerful tool to proteomics, enabling improved analysis of complex biological datasets. This integration has significantly enhanced the discovery of biomarkers for early diagnosis, disease stratification, and monitoring of therapeutic responses. Thus, cerebrospinal fluid and blood-based proteomic analyses have revealed promising candidates for neurological diseases. This review summarizes current advances in proteomics across a range of brain disorders, highlighting key molecular pathways, biomarker discovery efforts, and evolving clinical applications. Furthermore, it outlines future directions, including the application of machine learning for improved biomarker identification and precision medicine.